Related Experiment Video
Updated: Aug 1, 2026
Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications
Published on: November 17, 2015
[Study on third-type immunoliposomes loaded drugs and the targeting in vitro and in vivo]
1School of Pharmaceutical Science, Peking University, Beijing 100083, China. houxinpu@mail.bjmu.edu.cn
Aim:
To study the preparation, targeting and pharmacodynamics of third-type immunoliposome loaded anticancer drugs.
Methods:
The monoclonal antibody of human bladder cancer was combined with the terminal of PEG-COOH (polyethyleneglycol carboxylic acid) that make the liposomes not only prolong circulation by the membrane protection of PEG, but also target by spreading the antibody on the liposomes surface. That was the third type immunoliposomes. According to this scheme, the IML-ADM (immunoliposome carried adriamycin) wes prepared in which ADM entrapment was efficient and stability was high and the antibody activity was kept.
Results:
The % survival of the targeting EJ cells treated with IML-ADM (ADM = 45.45 micrograms.mL-1) was 4.3% +/- 1.0%, but 72% +/- 6% for non-targeting LOVO cells in vitro; the tumor weight in nude mice which were implanted by EJ cells after 27 days were (39 +/- 25) mg, (135 +/- 32) mg, (598 +/- 240) mg treated by IML-ADM, SSL-ADM (steric stable lipsomes carried Adriamycin) and normal saline, respectively, in vivo.
Conclusion:
The results confirmed that the immunoliposme-mediated targeting anticancer drug is a feasible way.
Insights
This study developed targeted immunoliposomes carrying anticancer drugs, showing significant efficacy against bladder cancer cells in vitro and in vivo. These targeted drug delivery systems offer a promising approach for cancer therapy.
Area of Science:
- Biotechnology
- Nanomedicine
- Drug Delivery Systems
Context:
- Developing targeted drug delivery is crucial for improving cancer treatment efficacy and reducing side effects.
- Traditional chemotherapy faces challenges with non-specific distribution and rapid clearance.
- Immunoliposomes offer a novel platform for site-specific drug delivery.
Purpose:
- To prepare and characterize third-type immunoliposomes for targeted delivery of anticancer drugs.
- To evaluate the targeting efficiency and pharmacodynamics of immunoliposomes loaded with adriamycin (ADM).
- To assess the in vitro and in vivo efficacy of immunoliposome-mediated drug delivery against human bladder cancer cells.
Summary:
- Third-type immunoliposomes were constructed by conjugating a human bladder cancer monoclonal antibody to PEG-COOH-modified liposomes, enhancing circulation time and targeting specificity.
- Immunoliposomes carrying adriamycin (IML-ADM) demonstrated efficient drug entrapment, high stability, and preserved antibody activity.
- In vitro studies showed IML-ADM selectively targeted EJ bladder cancer cells, while in vivo studies in nude mice demonstrated significant tumor growth inhibition compared to non-targeted liposomes and saline.
Impact:
- The study validates immunoliposome-mediated targeted drug delivery as a feasible and effective strategy for anticancer therapy.
- This approach holds potential for improving therapeutic outcomes in bladder cancer and other malignancies.
- Further research into immunoliposome formulations could lead to more potent and selective cancer treatments.
More Related Videos
08:44Preparation, Administration, and Assessment of In Vivo Tissue-Specific Cellular Uptake of Fluorescent Dye-Labeled Liposomes
Published on: July 30, 2020
08:46Cell-Free Production of Proteoliposomes for Functional Analysis and Antibody Development Targeting Membrane Proteins
Published on: September 22, 2020
